These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 16329283)

  • 1. CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection.
    Westby M; van der Ryst E
    Antivir Chem Chemother; 2005; 16(6):339-54. PubMed ID: 16329283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CCR5 antagonists in the treatment of treatment-naive patients infected with CCR5 tropic HIV-1.
    Bredeek UF; Harbour MJ
    Eur J Med Res; 2007 Oct; 12(9):427-34. PubMed ID: 17933724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals.
    Irlbeck DM; Amrine-Madsen H; Kitrinos KM; Labranche CC; Demarest JF
    AIDS; 2008 Jul; 22(12):1425-31. PubMed ID: 18614865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [CCR5 antagonists: a new class of antiretrovirals].
    de la Tribonnière X; Yazdanpanah Y; Reynes J
    Med Mal Infect; 2008 Mar; 38 Suppl 1():S1-6. PubMed ID: 18455055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of HIV infection by CXCR4 and CCR5 chemokine receptor antagonists.
    De Clercq E; Schols D
    Antivir Chem Chemother; 2001; 12 Suppl 1():19-31. PubMed ID: 11594685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV co-receptors as targets for antiviral therapy.
    Schols D
    Curr Top Med Chem; 2004; 4(9):883-93. PubMed ID: 15134547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CCR5 antagonists in the treatment of treatment-experienced patients infected with CCR5 tropic HIV-1.
    Lorenzen T; Stoehr A; Walther I; Plettenberg A
    Eur J Med Res; 2007 Oct; 12(9):419-25. PubMed ID: 17933723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How will CCR5 antagonists influence the recommendations for the antiretroviral treatment of HIV-1 infection.
    van Lunzen J
    Eur J Med Res; 2007 Oct; 12(9):435-40. PubMed ID: 17933725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-receptor antagonists as HIV-1 entry inhibitors.
    Shaheen F; Collman RG
    Curr Opin Infect Dis; 2004 Feb; 17(1):7-16. PubMed ID: 15090884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vicriviroc, a CCR5 receptor antagonist for the potential treatment of HIV infection.
    Klibanov OM
    Curr Opin Investig Drugs; 2009 Aug; 10(8):845-59. PubMed ID: 19649929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [CCR5 antagonists: a new class of antiretrovirals].
    Peytavin G; Calvez V; Katlama C
    Therapie; 2009; 64(1):9-16. PubMed ID: 19463248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient.
    Symons J; van Lelyveld SF; Hoepelman AI; van Ham PM; de Jong D; Wensing AM; Nijhuis M
    J Antimicrob Chemother; 2011 Apr; 66(4):890-5. PubMed ID: 21393136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions--review of the literature.
    Emmelkamp JM; Rockstroh JK
    Eur J Med Res; 2007 Oct; 12(9):409-17. PubMed ID: 17933722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Agonist-induced internalization of CC chemokine receptor 5 as a mechanism to inhibit HIV replication.
    Ferain T; Hoveyda H; Ooms F; Schols D; Bernard J; Fraser G
    J Pharmacol Exp Ther; 2011 Jun; 337(3):655-62. PubMed ID: 21389095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maraviroc: a new CCR5 antagonist.
    Sayana S; Khanlou H
    Expert Rev Anti Infect Ther; 2009 Feb; 7(1):9-19. PubMed ID: 19622053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro.
    Svicher V; Balestra E; Cento V; Sarmati L; Dori L; Vandenbroucke I; D'Arrigo R; Buonomini AR; Van Marck H; Surdo M; Saccomandi P; Mostmans W; Aerssens J; Aquaro S; Stuyver LJ; Andreoni M; Ceccherini-Silberstein F; Perno CF
    Antiviral Res; 2011 Apr; 90(1):42-53. PubMed ID: 21349294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The promise of CCR5 antagonists as new therapies for HIV-1.
    Repik A; Richards KH; Clapham PR
    Curr Opin Investig Drugs; 2007 Feb; 8(2):130-9. PubMed ID: 17328229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small-molecule antagonists of CCR5 and CXCR4: a promising new class of anti-HIV-1 drugs.
    Seibert C; Sakmar TP
    Curr Pharm Des; 2004; 10(17):2041-62. PubMed ID: 15279544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and characterization of INCB9471, an allosteric noncompetitive small-molecule antagonist of C-C chemokine receptor 5 with potent inhibitory activity against monocyte migration and HIV-1 infection.
    Shin N; Solomon K; Zhou N; Wang KH; Garlapati V; Thomas B; Li Y; Covington M; Baribaud F; Erickson-Viitanen S; Czerniak P; Contel N; Liu P; Burn T; Hollis G; Yeleswaram S; Vaddi K; Xue CB; Metcalf B; Friedman S; Scherle P; Newton R
    J Pharmacol Exp Ther; 2011 Jul; 338(1):228-39. PubMed ID: 21459966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV chemokine receptor inhibitors as novel anti-HIV drugs.
    Princen K; Schols D
    Cytokine Growth Factor Rev; 2005 Dec; 16(6):659-77. PubMed ID: 16005254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.